news

DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference

May 18, 2022, 13:53 ET CUPERTINO, Calif., May 18, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Dr. Norman Sussman, Chief Medical Officer, and Dr. WeiQi Lin, Executive Vice President of R&D, will be participating in a fireside chat hosted by Ed Arce, Managing Director of …

DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference Read More »

DURECT Corporation Reports First Quarter 2022 Financial Results and Update of Programs

– Webcast of Earnings Call Today, May 4th at 4:30 p.m. ET – Adding new clinical sites and patient dosing progressing in the AHFIRM trial CUPERTINO, Calif., May 4, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2022 and provided a corporate update. “Progress continues …

DURECT Corporation Reports First Quarter 2022 Financial Results and Update of Programs Read More »

DURECT Corporation to Announce First Quarter 2022 Financial Results and Provide Business Update on May 4

CUPERTINO, Calif., April 27, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2022 financial results and host a conference call after the market close on Wednesday, May 4, 2022. Wednesday, May 4 @ 4:30pm Eastern Time / 1:30pm Pacific Time Toll Free:                               1-800-285-6670 International:                        713-481-1320 …

DURECT Corporation to Announce First Quarter 2022 Financial Results and Provide Business Update on May 4 Read More »

DURECT Corporation To Present at the 2022 Cantor Fitzgerald Virtual Rare Orphan Disease Summit

CUPERTINO, Calif., March 23, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, will be participating in a panel discussion at the Cantor Virtual Rare Orphan Disease Summit hosted by Kristen Kluska, Managing Director, Biotechnology Research Analyst of Cantor Fitzgerald.  The title of the panel is “Small but Mighty: …

DURECT Corporation To Present at the 2022 Cantor Fitzgerald Virtual Rare Orphan Disease Summit Read More »

DURECT Corporation Fireside Chat at the Oppenheimer 32nd Annual Healthcare Conference

CUPERTINO, Calif., March 9, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Dr. WeiQi Lin, Executive Vice President of R&D and Dr. Norman Sussman, Chief Medical Officer, will be participating in a fireside chat hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer & …

DURECT Corporation Fireside Chat at the Oppenheimer 32nd Annual Healthcare Conference Read More »

DURECT Corporation Reports Fourth Quarter and Full Year 2021 Financial Results and Update of Programs

– Webcast of Earnings Call Today, March 7th at 4:30 p.m. ET – Dosed first patient in Europe in the AHFIRM trial – Signed a licensing agreement for POSIMIR® for up to $136M CUPERTINO, Calif., March 7, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December …

DURECT Corporation Reports Fourth Quarter and Full Year 2021 Financial Results and Update of Programs Read More »

DURECT Corporation Doses First European Patient in Phase 2b AHFIRM Study of Larsucosterol(DUR-928) in Severe Alcohol-Associated Hepatitis

CUPERTINO, Calif., March 1, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced it dosed the first patient in the European Union as part of its AHFIRM randomized, double-blind, placebo-controlled, multi-center Phase 2b study to evaluate the safety and efficacy of larsucosterol in severe alcohol-associated hepatitis (AH) patients. “Dosing the first patient in Europe is an …

DURECT Corporation Doses First European Patient in Phase 2b AHFIRM Study of Larsucosterol(DUR-928) in Severe Alcohol-Associated Hepatitis Read More »

DURECT Corporation to Announce Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on March 7

CUPERTINO, Calif., Feb. 28, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and full year 2021 financial results and host a conference call after the market close on Monday, March 7, 2022. Monday, March 7 @ 4:30pm Eastern Time / 1:30pm Pacific Time Toll Free:      …

DURECT Corporation to Announce Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on March 7 Read More »

DURECT Corporation to Participate in H.C. Wainwright Bioconnect Conference

CUPERTINO, Calif., Jan. 6, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, and Dr. Norman Sussman, Chief Medical Officer will present at the H.C. Wainwright Bioconnect Conference which will be available on demand starting on January 10, 2022. Presentation details are as follows: H.C. …

DURECT Corporation to Participate in H.C. Wainwright Bioconnect Conference Read More »

DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR® (Bupivacaine Solution)

– DURECT to receive near-term upfront cash payments totaling $6 million, potential additional milestone payments of up to $130 million and tiered low to mid double-digit royalties based on U.S. sales – Innocoll granted exclusive development and commercialization rights to POSIMIR in the United States – DURECT to discuss agreement on Conference Call and Webcast …

DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR® (Bupivacaine Solution) Read More »

Scroll to Top